Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Rituximab 47Cyclophosphamide 26fludarabine 13ibrutinib 12Doxorubicin 11Vincristine 10Etoposide 10Cytarabine 10Prednisone 9Bortezomib 9pembrolizumab 7fludarabine phosphate 6Lenalidomide 6Inotuzumab Ozogamicin 6obinutuzumab 5Mycophenolic Acid 5Melphalan 5Carmustine 5tositumomab I-131 4ibritumomab tiuxetan 4Tacrolimus 4Prednisolone 4Methotrexate 4Gemcitabine 4Bendamustine Hydrochloride 4Antilymphocyte Serum 4tocilizumab 3tazemetostat 3Whole-Body Irradiation 3Vorinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, B-Cell × gemcitabine-oxaliplatin regimen × Clear all
NCT00169195 2015-09-02

Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Lymphoma Study Association

Phase 2 Completed
49 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡